Health Protection Agency Launches new Research Centre for Studying Nanotoxicology
News Jul 25, 2008
The Health Protection Agency has set up a new centre to study the possible health effects of human exposure to nanoparticles. The National Nanotoxicology Research Centre (NNRC) is being developed at the Agency’s Centre for Radiation, Chemical and Environmental Hazards (CRCE) at Chilton in Oxfordshire.
The Agency is collaborating with universities and the Medical Research Council's (MRC) Toxicology Unit to develop the centre and its research programme.
The Agency's Chairman Sir William Stewart said: “The application of nanotechnology is an exciting development with many potential benefits. However, it is very new technology and some element of precaution is required. More research should be carried out into any possible health effects from the use of nanoparticles, and that is the primary task of the new centre.”
The Agency will be collaborating with the Universities of Birmingham, Cardiff, Edinburgh, Imperial College and King’s College London and the MRC Toxicology Unit in Leicester.
Nanotechnology uses materials of dimensions measured in nanometers (1 x 10-9 metres or 0.000001 millimetres). Such materials can have unusual physicochemical properties which make them useful in applications including medicine, electronics, optical-electronic systems and imaging. They are also used in cosmetic and food products.
Knowledge of the possible interactions between nanomaterials and the body is developing rapidly. NNRC will focus, initially, on the behaviour of nanomaterials that enter the body via the lung and skin. The transportation of nanomaterials in the body will be studied and special emphasis will be placed on investigating the bio-kinetics of nanoparticles. This will involve studies of their entry into the body, their distribution within and their removal from the body.
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Study Debunks Fears of Increased Teen Suicide Risk From TamifluNews
Researchers from the University of Illinois at Chicago suggests that the drug oseltamivir - commonly known as Tamiflu - does not cause an increased risk of suicide in pediatric patients.READ MORE